DIOSynVax is revolutionizing vaccine antigen payload development
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, selecting the best Vaccine Antigen Payload (VAP) candidates while growing a reservoir of data that continually improves our designs.
Collaborators
We partner with leading organisations to advance innovative vaccine solutions and protect global health
Latest News
Stay informed with the latest updates from DIOSynVax, including advancements in our vaccine development programs, strategic partnerships, and industry insights.
October 2026
The DIOSynVax-led programme will advance DVX-HFVac3 towards clinical trials, with the vaccine designed to provide broad protection against Lassa fever, Marburg virus and Sudan ebolavirus.
October 2026
DIOSynVax and the University of Cambridge have secured £4.28 million in UK Government funding to advance DVX-HFVac3 towards clinical trials — a vaccine designed to protect against Lassa, Marburg and Sudan ebolavirus.
September 2026
DIOSynVax brings together genomics, synthetic biology, artificial intelligence (AI), and immunology to design broadly protective vaccine antigens that are compatible with most vaccine delivery systems.